Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:GWW
NYSE:GWWTrade Distributors

Evaluating W.W. Grainger (GWW) After Recent Share Price Choppiness

Stock performance snapshot and recent returns W.W. Grainger (GWW) has drawn investor attention after a recent share price around $1,054.47, with a 1 day return of 1.2% and mixed performance across the week, month, and past 3 months. See our latest analysis for W.W. Grainger. Recent trading has been choppy, with a 30 day share price return showing a 6.44% decline, which contrasts with a 5.05% year to date share price gain and a 5 year total shareholder return of 177.80%. This suggests that...
TSX:KXS
TSX:KXSSoftware

How Investors May Respond To Kinaxis (TSX:KXS) Slashing Maestro Planning Times With NVIDIA AI

In March 2026, Kinaxis Inc. reported a major milestone for its Maestro supply chain platform, using NVIDIA cuOpt and NVIDIA AI infrastructure to shrink end-to-end optimization runtimes on a large semiconductor model from more than three hours to about 17 minutes while preserving solution quality. This acceleration, achieved on a model with nearly 50 million decision variables and more than 40,000 SKUs, shifts supply chain planning from slow batch runs to interactive scenario testing,...
NYSE:AXP
NYSE:AXPConsumer Finance

Is It Too Late To Consider American Express (AXP) After Recent Share Price Pullback?

Wondering whether American Express at around US$301.91 is still offering value, or if most of the upside is already reflected in the price. The stock has posted a 1.2% return over the last 7 days, a 12.8% decline over 30 days, is down 19.0% year to date, yet shows a 9.8% return over 1 year, 91.9% over 3 years and 125.3% over 5 years. This raises fair questions about timing and risk. Recent headlines have focused on American Express as a long term compounder in consumer finance, with...
NYSE:GFF
NYSE:GFFBuilding

Steep Revenue Forecast Cut Might Change The Case For Investing In Griffon (GFF)

In recent commentary, Griffon (NYSE:GFF) was reported to be facing ongoing end-market challenges, with sales declining by 2.7% annually over the past two years and analysts forecasting a further 28.7% revenue decline over the next 12 months, signalling weaker demand across its home improvement and building products portfolio. This sharp expected revenue drop, coming on top of a multi-year sales decline, raises questions about how much internal efficiency gains and product innovation can...
NYSE:VVX
NYSE:VVXAerospace & Defense

Assessing V2X (VVX) Valuation After New Elastic Partnership In Defense Data Solutions

V2X (VVX) shares are in focus after the company announced a new collaboration with Elastic, aimed at strengthening search, analytics, and data-driven mission support for government, defense, and intelligence clients. See our latest analysis for V2X. The collaboration with Elastic lands at a time when momentum in V2X shares has been building. The 90 day share price return of 24.67% sits alongside a 1 year total shareholder return of 35.89% and 3 year total shareholder return of 76.26%. This...
NYSE:IONQ
NYSE:IONQTech

IonQ’s Global Quantum-AI Partnerships Might Change The Case For Investing In IonQ (IONQ)

In March 2026, IonQ announced a series of partnerships, including a Quantum Innovation Centre with the University of Cambridge and an MOU with Korea Institute of Science and Technology Information to integrate its quantum hardware with NVIDIA-enabled high-performance computing infrastructure. These collaborations, alongside IonQ’s work with US federal agencies on secure quantum architectures, highlight how the company is positioning its platform at the intersection of quantum computing, AI,...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead Expands Into Autoimmune With Ouro Deal And Galapagos Alliance

Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Ouro Medicines, adding an FDA fast-tracked, orphan-designated T cell engager for autoimmune diseases to its pipeline. The company is also entering a major research partnership with Galapagos to co-develop and commercialize this first-in-class clinical asset for severe autoimmune conditions. These moves extend Gilead’s recent deal activity beyond oncology and broaden its inflammation and immunology portfolio. For you as an investor, this...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

Is BeOne Medicines (ONC) Pricing In Too Much Optimism After Recent Share Price Drop?

If you are wondering whether BeOne Medicines at US$274.73 is still a fair deal or already pricing in a lot of optimism, the valuation picture is the place to start. The stock has been volatile recently, with a 5.2% decline over the last week and a 24.1% decline over the last 30 days. Over longer periods, the 1 year return sits at 8.5% and the 3 year return at 22.2%, while the 5 year return is a 15.1% decline. Recent news coverage has focused on BeOne Medicines as part of the broader...
ENXTPA:ELIS
ENXTPA:ELISCommercial Services

Elis Taps €600 Million Bond To Rebalance Debt And Fund Buybacks

Elis (ENXTPA:ELIS) has priced €600 million in senior unsecured notes under its EMTN programme. The funds are intended for debt refinancing and a new share buyback program. The placement was strongly oversubscribed, indicating solid demand from investors. Elis, a provider of textile, hygiene and facility services, operates in sectors where clients often rely on long term outsourcing contracts, from hospitality and healthcare to industry. Recent years have kept attention on operational...
NYSE:BOOT
NYSE:BOOTSpecialty Retail

How Boot Barn’s Push into Underpenetrated High‑Growth States Could Reshape Boot Barn Holdings (BOOT) Investors

Recent commentary in March 2026 highlighted Boot Barn Holdings’ rapid store expansion across Texas, California, Florida, and Oklahoma, where new locations in underpenetrated markets have been generating stronger-than-expected performance and supporting expectations for higher demand and revenue over the coming year. An interesting angle is how this expansion into growth markets appears to be boosting customer acquisition and sales productivity, suggesting store rollout quality and market...
NYSE:LEN
NYSE:LENConsumer Durables

A Look At Lennar (LEN) Valuation After Q1 Earnings, Guidance Update And Buyback Progress

Lennar (LEN) shares are in focus after the homebuilder reported first quarter results showing lower revenue and net income year over year, issued new second quarter home delivery guidance, and updated investors on its multi year share repurchase program. See our latest analysis for Lennar. The earnings report and guidance update came against a backdrop of weaker momentum, with a 30 day share price return of 19.75% and a 1 year total shareholder return of 19.08%. The 3 year and 5 year total...
NasdaqGM:RZLV
NasdaqGM:RZLVSoftware

Rezolve AI (RZLV) Valuation Check As 2025 Results And Shoptalk 2026 Showcase Draw Closer

Rezolve AI (RZLV) heads into a busy week for investors, with its 2025 financial results due on March 30, 2026, and a high profile showcase of its agentic commerce platform at Shoptalk 2026. See our latest analysis for Rezolve AI. Rezolve AI's share price has climbed 26.5% over the past month but is still showing a 5.2% year to date share price decline, while the 1 year total shareholder return of 65.9% contrasts with a 3 year total shareholder loss of roughly 73.0%. This hints that recent...
NYSE:RAMP
NYSE:RAMPSoftware

Brian O’Kelley Resigns From LiveRamp Board Raising Governance Questions

LiveRamp Holdings director Brian O'Kelley has resigned from the Board. His departure removes a board member with industry experience in ad tech and data. The change adds a new governance factor for investors tracking NYSE:RAMP. LiveRamp Holdings (NYSE:RAMP) is drawing fresh attention after this boardroom change, with the share price recently at $27.41. Over the past 3 years the stock has returned 28.8%, while the 5-year return stands at a 45.9% decline, a mixed backdrop that can shape how...
CPSE:GMAB
CPSE:GMABBiotechs

Genmab (CPSE:GMAB) Valuation Check As Amlenetug Clinical Progress Draws Fresh Investor Attention

Lundbeck’s new clinical data on Lu AF28996 and the amlenetug program at the 2026 AD/PD conference has refocused attention on Genmab (CPSE:GMAB), given its collaboration role in developing amlenetug. See our latest analysis for Genmab. At a share price of DKK1,655.5, Genmab has a 1 day share price return of 1.13%, following a 30 day share price return decline of 10.68% and a 90 day share price return decline of 22.02%. The 1 year total shareholder return of 24.94% contrasts with weaker 3 and 5...
NYSE:DAL
NYSE:DALAirlines

Assessing Delta Air Lines (DAL) Valuation After Mixed Short-Term Share Price Moves

Delta Air Lines stock moves after mixed recent returns Delta Air Lines (DAL) has seen a 2.7% move over the past day and a 7.1% gain over the past week, while the share price shows declines over the month and the past 3 months. See our latest analysis for Delta Air Lines. Set against a share price of US$65.13, Delta's recent 1-day and 7-day share price returns contrast with weaker 1-month, 3-month and year to date figures, while its 1-year and multi year total shareholder returns remain...
ENXTPA:CA
ENXTPA:CAConsumer Retailing

Carrefour (ENXTPA:CA) Valuation Check As Recent Pullback Meets Conflicting Analyst Signals

Why Carrefour stock is drawing attention now Carrefour (ENXTPA:CA) is back on many investors’ screens after recent share price moves, with the stock showing a mix of shorter term weakness and longer term strength across different time frames. See our latest analysis for Carrefour. The recent pullback, including a 1-day share price return of a 1.57% decline and a 7-day share price return of a 4.40% decline, sits against a 1-year total shareholder return of 26.84%. This suggests momentum has...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

A Look At Science Applications International (SAIC) Valuation After Earnings Miss And Revenue Decline

Science Applications International (SAIC) stock is in focus after the company reported a year over year revenue decline and missed Wall Street expectations, while management outlined a shift toward higher value contracts and cost efficiencies. See our latest analysis for Science Applications International. The recent earnings miss, revenue decline and fresh guidance for fiscal 2027 have come alongside active capital actions such as share repurchases and a continued dividend. The share price...
NYSE:CC
NYSE:CCChemicals

Should Chemours’ $700 Million Debt Refinance Require Action From Chemours (CC) Investors?

The Chemours Company recently completed a private offering of US$700,000,000 in 7.875% senior unsecured notes due 2034 and used the proceeds, alongside cash on hand, to redeem portions of its 5.750% senior notes due 2028 and plans to redeem its 5.375% senior notes due 2027. This refinancing reshapes Chemours' debt profile by extending maturities and altering interest costs, which can influence perceptions of its financial flexibility and risk. Next, we will examine how Chemours’ use of new...
NYSE:HTGC
NYSE:HTGCCapital Markets

A Look At Hercules Capital’s (HTGC) Valuation After New Class Action Lawsuit Over Portfolio Practices

Class action lawsuit puts Hercules Capital’s processes under scrutiny Hercules Capital (HTGC) is under fresh legal scrutiny after a new class action lawsuit tied to allegations about its deal sourcing, portfolio valuation practices, and classification of software related debt exposure. The complaint, filed following a Hunterbrook Media report and a sharp single day share price drop in February 2026, raises questions around the company’s internal controls and past disclosures to investors. See...
NasdaqGS:NSIT
NasdaqGS:NSITElectronic

Insight Enterprises (NSIT) Valuation Check As Major Leadership Transition Takes Shape

Insight Enterprises (NSIT) shares are in focus after the company announced a broad leadership transition, with Jack Azagury set to become President, CEO and board member on April 13, 2026. See our latest analysis for Insight Enterprises. The leadership reshuffle comes at a time when Insight Enterprises' share price has eased back, with a 7 day share price return of 12.63% and a 30 day share price return of 16.82% decline, while the 1 year total shareholder return of 55.67% decline points to...
ENXTPA:AIR
ENXTPA:AIRAerospace & Defense

Assessing Airbus (ENXTPA:AIR) Valuation After Recent Share Price Momentum Shifts

Why Airbus stock is back on investors’ radar Airbus (ENXTPA:AIR) has caught investor attention after a period where the share price shows mixed recent returns, including a 3.4% gain over the past day and a decline over the past month. See our latest analysis for Airbus. The recent 1 day share price return of 3.41% comes after a weaker spell, with the 30 day share price return of 12.30% and year to date share price return of 18.31%. In contrast, the 5 year total shareholder return of 82.84%...
NasdaqGS:BKR
NasdaqGS:BKREnergy Services

Baker Hughes Taps Google Cloud As Data Center And LNG Story Grows

Baker Hughes announced a major collaboration with Google Cloud to build AI enabled power optimization tools for global data centers. The company also reported large new equipment contracts tied to both hyperscale data center power needs and LNG export projects. These moves extend Baker Hughes' reach further into digital infrastructure energy and add to its LNG equipment backlog. Baker Hughes, listed as NasdaqGS:BKR, is leaning into data center power infrastructure at a time when digital...
NYSE:VIK
NYSE:VIKHospitality

Viking Libra Hydrogen Launch Adds New Dimension To Viking Holdings Story

Viking Holdings (NYSE:VIK) has floated out the Viking Libra, the world’s first hydrogen powered cruise ship. The vessel marks a key step toward zero emission cruising and is intended to address demand for lower impact travel options. This event has not been covered in recent updates and adds a new angle to the Viking Holdings story for investors. Viking Holdings, trading at $71.87, is coming off a 73.5% return over the past year, with shorter term moves including a 0.9% gain over the past...
NYSE:LMT
NYSE:LMTAerospace & Defense

Lockheed Martin Faces Rare Earth Squeeze As F-35 And Margins Tested

Lockheed Martin (NYSE:LMT) is accelerating rare earth procurement and dual-sourcing after new Pentagon rules and active military operations began drawing down existing US stockpiles. The company sits at the center of an emerging rare earths supply crunch that touches core programs, including advanced platforms such as the F-35. Fresh regulatory deadlines and real-time combat demands are reshaping how LMT sources critical materials, with increased reliance on multiple suppliers and tighter...